Case Details
- Citation: [2022] SGCA(I) 5
- Title: Kiri Industries Limited v Senda International Capital Limited & Anor
- Court: Court of Appeal of the Republic of Singapore (appeal from the Singapore International Commercial Court)
- Date: 6 July 2022
- Judges: Judith Prakash JCA, Robert French IJ, Jonathan Mance IJ
- Appellant/Applicant: Kiri Industries Limited
- Respondents: Senda International Capital Limited; DyStar Global Holdings (Singapore) Pte Ltd
- Other Appeal (reversed roles): Senda International Capital Limited v Kiri Industries Limited; DyStar Global Holdings (Singapore) Pte Ltd
- Procedural Origin: In the matter of SIC/Suit No 4 of 2017
- Civil Appeals: Civil Appeals Nos 7, 22 and 47 of 2021; Civil Appeals Nos 8, 45 and 48 of 2021
- Summonses: Summonses Nos 1 and 2 of 2022
- Legal Area: Corporate law; minority shareholder oppression; valuation of shares
- Statutes Referenced: Not specified in the provided extract
- Cases Cited: Not specified in the provided extract (other than references to the earlier SICC and Court of Appeal decisions)
- Judgment Length: 136 pages; 40,553 words
- Earlier Decisions (context): Main Judgment: DyStar Global Holdings (Singapore) Pte Ltd v Kiri Industries Ltd and others and another suit [2018] 5 SLR 1; Court of Appeal decision: Senda International Capital Ltd v Kiri Industries Ltd and others and another appeal [2019] 2 SLR 1
- SICC Valuation Judgments: First Valuation Judgment [2021] 3 SLR 215; Oral Judgment (17 March 2021); Second Valuation Judgment [2021] 5 SLR 1; Final Valuation Judgment [2021] 5 SLR 111
Summary
This decision concerns the valuation of a minority shareholder’s shares in DyStar Global Holdings (Singapore) Pte Ltd (“DyStar”) ordered as a remedy for oppressive conduct. The Court of Appeal was not revisiting the finding of oppression itself; rather, it addressed a complex set of valuation disputes arising from multiple SICC judgments that implemented the buyout order. The parties’ disagreement centred on how to quantify the financial consequences of oppressive acts, how to treat certain patent-related events, and how to apply valuation adjustments such as a discount for lack of marketability (“DLOM”), country risk premium, and other cost-of-equity components.
In substance, the Court of Appeal upheld the SICC’s overall approach to valuation methodology and its treatment of key adjustments, while also clarifying aspects of how valuation evidence should be assessed and how adjustments should be made. The Court’s reasoning reflects a strong deference to the SICC’s fact-sensitive evaluation of expert evidence, particularly where the SICC identified bias, unreliability, or evidential gaps in one party’s modelling assumptions.
What Were the Facts of This Case?
DyStar is part of a global group manufacturing and selling dyes. From 2012, Senda International Capital Ltd (“Senda”) became the majority shareholder of DyStar, holding 62.43% of its shares. Kiri Industries Ltd (“Kiri”) held the remaining 37.57%. In 2015, Kiri commenced proceedings alleging oppressive conduct by Senda. The oppression was linked to conduct by Zhejiang Longsheng Group Co Ltd (“Longsheng”), a company of which Senda was a wholly-owned subsidiary.
In the “Main Judgment” dated 3 July 2018, a three-judge coram of the Singapore International Commercial Court (“SICC”) found in favour of Kiri. The SICC ordered that Senda purchase Kiri’s 37.57% shareholding in DyStar. Importantly, the SICC directed that the valuation of Kiri’s shares should take into account the effects of various aspects of oppressive conduct by Longsheng. That decision was upheld on appeal by the Court of Appeal in 2019, confirming both the oppression finding and the remedial framework requiring a valuation that reflects the oppressive conduct’s financial impact.
After the buyout order, the parties returned to the SICC to determine how the shares should be valued. The SICC delivered four valuation judgments. The first, delivered on 21 December 2020, addressed valuation methodology and a series of adjustments to DyStar’s enterprise value. An oral judgment followed on 17 March 2021, and further written judgments were delivered on 3 June 2021 and 21 June 2021. The present Court of Appeal proceedings arose from appeals by both Kiri and Senda against aspects of those valuation decisions.
The factual disputes in the valuation proceedings were tightly linked to specific events and financial modelling assumptions. One central theme was the patent landscape affecting DyStar’s earnings and the downstream consequences of patent expirations. Another theme was the treatment of notional licence fees relating to the Orange 288 (“O288”) patent, which had been temporarily assigned to Longsheng for litigation defence in China and then exploited commercially without accounting to DyStar. The SICC had found that Longsheng’s conduct in exploiting the O288 patent and collecting licence fees from third parties without accounting to DyStar constituted an oppressive act. The valuation therefore required quantifying the financial effects of that oppressive conduct and adjusting DyStar’s enterprise value accordingly.
What Were the Key Legal Issues?
The Court of Appeal had to decide multiple legal issues, but they can be grouped into three broad categories. First, it had to address procedural and evidential questions, including whether the SICC properly rejected a hearsay objection to certain broker and market reports used by Kiri’s expert. This issue mattered because valuation is often grounded in market comparables and forecast information, and the admissibility and reliability of such material can affect the valuation outcome.
Second, the Court had to evaluate whether the SICC correctly applied valuation methodologies and made appropriate adjustments to enterprise value and, ultimately, to the value of Kiri’s shareholding. This included assessing how the SICC treated expert evidence, particularly where one party’s modelling assumptions were said to be unreliable, skewed, or insufficiently evidenced. The Court also had to consider whether the SICC’s approach to adjustments was consistent with the remedial objective of reflecting the effects of oppressive conduct.
Third, the Court had to determine the correctness of specific adjustment items. These included (as reflected in the extract) the treatment of notional and third-party licence fees for the O288 patent, the impact of patent expirations on DyStar’s maintainable earnings, the application of DLOM, and the accounting for country risk premium and other cost-of-equity components. The Court also addressed whether certain adjustments should be made (or not made) and how to quantify their quantum.
How Did the Court Analyse the Issues?
The Court of Appeal began by situating the appeals within the broader oppression remedy framework. The buyout order required a valuation that incorporates the effects of oppressive conduct. This meant that the valuation exercise was not a purely hypothetical market valuation; it was a remedial valuation designed to neutralise the financial consequences of oppression and to ensure that the minority shareholder is not disadvantaged by the oppressive acts. The Court therefore treated the SICC’s valuation adjustments as part of the remedial architecture rather than as discretionary “add-ons”.
On the hearsay objection, the Court examined whether the SICC was entitled to rely on broker and market reports and forecasts that were challenged as inadmissible hearsay. The SICC had generally preferred Kiri’s expert methodology and rejected Senda’s hearsay objections. The Court of Appeal’s analysis emphasised that valuation proceedings often involve expert reliance on market information. The key question was not merely formal admissibility but whether the material was sufficiently reliable for the purpose for which it was used and whether the SICC’s evidential assessment was justified. Where the SICC found that the reports and forecasts were used appropriately and that the opposing expert’s alternative assumptions were less reliable, the Court was reluctant to interfere.
Regarding valuation methodology and adjustments, the Court of Appeal focused heavily on the SICC’s evaluation of expert evidence. In the first valuation stage, the SICC preferred Ms Roula Harfouche’s valuation approach over Mr Lie’s. The SICC rejected Mr Lie’s reliance on April 2019 forecasts as unreliable and skewed in Senda’s favour. It also rejected a “February 2020 Model” that purported to quantify risk events negatively impacting DyStar’s valuation, finding that many assumptions were not backed by evidence and that the circumstances suggested the model had been prepared specifically for the valuation proceedings and consciously skewed in Senda’s favour.
In reviewing the SICC’s approach, the Court of Appeal underscored the importance of evidential grounding for valuation assumptions. Where the SICC identified that a modelling exercise was based on assumptions lacking evidential support, or where it found that the assumptions were tailored to produce a desired outcome, the SICC could reasonably discount that evidence. This approach is consistent with the broader principle that expert evidence must be anchored in reliable data and sound reasoning, particularly in valuation disputes where small changes in assumptions can have large effects on the final valuation.
Several specific adjustment issues illustrate the Court’s reasoning. First, the SICC accepted Ms Harfouche’s valuation of US$1,636m but required nine adjustments. One adjustment concerned notional licence fees payable by Longsheng for its use of the O288 patent. The SICC’s reasoning reflected the remedial purpose: because Longsheng had exploited the O288 patent and collected licence fees from third parties without accounting to DyStar, the valuation had to incorporate a notional licence fee to reflect the oppressive conduct’s financial effects. The SICC rejected Kiri’s suggestion to quantify benefits obtained by Longsheng through an “account of profits” approach, instead calculating a notional licence fee based on the quantity of products manufactured using and falling within the scope of the O288 patent (“Related Products”). The SICC also held that litigation costs incurred by Longsheng in defending the O288 patent should not be deducted from the notional licence fee, because the terms of the patent assignment indicated those costs were borne by Longsheng.
Second, the SICC made adjustments for downstream financial impacts of patent expirations. For the O288 patent, it deducted US$6.5m from maintainable EBITDA to reflect the effect of expiration. For other patents used in producing Indigo 40% (“I40 Patents”), it deducted US$17.2m as suggested by Mr Lie. These adjustments required the Court to consider whether the SICC’s approach to forecasting the financial impact of patent expiry was consistent with the valuation methodology and the evidential record.
Third, the Court addressed cost-of-equity adjustments and risk premia. The SICC applied a DLOM of 19% to the value of Kiri’s shareholding. It also accounted for a country risk premium of 1.6% in DyStar’s cost of equity. The Court’s analysis treated these as valuation inputs that must be justified by the evidence and by the logic of the valuation model. Where the SICC had explained why particular premia were appropriate and why alternative approaches were not, the Court was generally prepared to uphold the SICC’s conclusions.
Finally, the Court considered whether further downward adjustments were required on account of patent expirations, and whether a DLOM should be applied in valuing Kiri’s shareholding. The Court also addressed the treatment of exploitation benefits for Longsheng’s use of the O288 patent, including whether the benefit should be accounted for as an “account of profits” or as a notional licence fee. The Court’s reasoning indicates that the remedial valuation must be coherent: the method chosen must align with the nature of the oppressive conduct and the valuation objective, rather than importing accounting concepts in a way that duplicates or distorts the valuation adjustments already made.
What Was the Outcome?
The Court of Appeal dismissed or did not grant the relief sought in the appeals, thereby upholding the SICC’s valuation framework and its key adjustments. The practical effect was that the buyout valuation of Kiri’s 37.57% shareholding in DyStar remained anchored in the SICC’s enterprise value computation, including the notional licence fee adjustment for the O288 patent, the patent-expiration EBITDA deductions, the application of DLOM, and the country risk premium treatment.
By confirming the SICC’s approach to expert evidence and valuation adjustments, the Court reinforced that, in oppression buyouts, valuation is a remedial exercise requiring careful quantification of oppressive conduct’s financial consequences. The outcome therefore provided finality to the valuation stage and enabled the parties to implement the buyout order on the basis of the SICC’s valuation determinations as affirmed by the Court of Appeal.
Why Does This Case Matter?
This case is significant for practitioners because it illustrates how Singapore courts handle valuation in minority oppression buyouts where the valuation must reflect the effects of oppressive conduct. Unlike ordinary share valuation disputes, the valuation here is explicitly remedial. The Court of Appeal’s endorsement of the SICC’s methodology and evidential assessment provides guidance on how to structure expert evidence and how to justify valuation assumptions when the valuation is intended to neutralise oppression-related financial distortions.
Second, the decision offers practical lessons on expert modelling. The Court’s reasoning shows that courts will scrutinise whether an expert’s assumptions are supported by evidence, whether forecasts are reliable, and whether models appear tailored to achieve a particular outcome. For litigators, this underscores the importance of ensuring that valuation models are built on transparent, defensible inputs and that any reliance on market reports or forecasts is supported by a reliability rationale.
Third, the case is useful for lawyers dealing with intellectual property-related oppression and patent expiry effects. The Court’s treatment of notional licence fees, and its rejection of an “account of profits” approach in favour of a licence-fee quantification aligned with the scope of the patent and the products manufactured, provides a structured way to translate oppressive IP exploitation into valuation adjustments.
Legislation Referenced
- Not specified in the provided extract.
Cases Cited
- DyStar Global Holdings (Singapore) Pte Ltd v Kiri Industries Ltd and others and another suit [2018] 5 SLR 1 (“Main Judgment”)
- Senda International Capital Ltd v Kiri Industries Ltd and others and another appeal [2019] 2 SLR 1
- Kiri Industries Ltd v Senda International Capital Ltd and another [2021] 3 SLR 215 (“First Valuation Judgment”)
- Kiri Industries Ltd v Senda International Capital Ltd and another [2021] 5 SLR 1 (“Second Valuation Judgment”)
- Kiri Industries Ltd v Senda International Capital Ltd and another [2021] 5 SLR 111 (“Final Valuation Judgment”)
Source Documents
This article analyses [2022] SGCAI 5 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.